Video

Pioneer in Supportive Care Research Discusses History of Emesis Management

Dr. Ricahrd J Gralla discusses the history of the early medical oncology space and how things have changed when it comes to treating side effects related to chemotherapy.

Emesis, the medical term for vomiting, is one of the most common side effects associated with cancer treatment, especially chemotherapy. But now the field has a host of antiemetic drugs to help prevent vomiting, a reality that wasn’t the case in the early days of medical oncology.

Dr. Richard J. Gralla was one of the leaders in the early medical oncology field looking at making supportive care an integral part of cancer care. Part of his work involved having patients with lung cancer take antiemetics to help prevent vomiting and avoid treatment discontinuation due to side effect fears.

In an interview with CURE® Gralla, director of oncology research for the North Bronx Healthcare Network, spoke about what the early days of research into cancer treatment-related emesis looked like and where supportive care stands now in the lung cancer space.

Transcription:

In those early days, when we were thinking what we should do, we needed to look at something a little different. Basically, over two or three days, or even less, I read the world's literature on clinical studies in emesis. It didn't take very long. However, these two pioneers, Boris and McCarthy, and several others had really worked out the physiology of emesis. And most of us really have not been well educated in reading their views and understanding the clinical problem.

We were able to look at some different areas, and then, because we've done work in phase one, said, hey, are we giving the right doses of these drugs? And then when we found ways that were working, the question came up: how are these working? And then it was through collaboration with some neuro pharmacologists, who were so bright and said, we think that these must be working in this pathway, not the original pathway, and the drugs that work in that pathway might be safer and more effective. And so that was kind of a fun way of putting that together. But then seeing the clinical aspect of it, as that nurse expressed to me, yeah, that’s true.

Then, one of my other interests has been in day hospitals, and doing (treatment) without overnight admissions in many, many aspects, and having proper antiemetics is kind of important for that. And then measuring, from a quality of life standpoint, do patients agree with us, and well let's hear the patient's voice. So, hearing those things together, has been very interesting and rewarding at the same time.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Image of man with text.
An expert highlights the impact of anemia in myelofibrosis and presented Ojjaara as a possible treatment to reduce transfusions and improve outcomes.
After ovarian cancer surgery, Mary Barbera spent three months in rehab before finally returning home, a milestone that marked her emotional recovery.
Terry Gillespie said the hardest parts of her cancer journey were the isolation, the impact of chemotherapy, and how unprepared she felt despite good guidance.
Dr. Erika Hamilton says social media and professional guidelines help patients stay informed about fast-changing breast cancer treatments and advances.
Outpatient CAR T-cell therapy has reduced hospital stays by two-thirds while maintaining safety for those with blood cancers, according to Dr. Olalekan Oluwole.
Dr. Masey Ross explains how biomarker testing, patient history, and quality-of-life concerns guide treatment decisions in metastatic breast cancer.
Dr. Paolo Tarantino shares how antibody-drug conjugates deliver more targeted chemo, and how the treatment lasts longer in the body vs traditional therapy.
Image of women with text.
The inMIND trial led to the FDA approval of Monjuvi with Revlimid and Rituxan for relapsed follicular lymphoma, showing benefits across diverse patients.